O	0	3	The
O	4	12	addition
O	13	15	of
O	16	17	a
B-intervention	18	23	boost
I-intervention	24	28	dose
O	29	31	on
O	32	35	the
O	36	43	primary
O	44	50	tumour
O	51	54	bed
O	55	60	after
O	61	71	lumpectomy
O	72	74	in
O	75	81	breast
O	82	92	conserving
O	93	102	treatment
O	103	106	for
O	107	113	breast
O	114	120	cancer
O	120	121	.

O	122	123	A
O	124	131	summary
O	132	134	of
O	135	138	the
O	139	146	results
O	147	149	of
O	150	155	EORTC
O	156	161	22881
O	161	162	-
O	162	167	10882
O	168	169	"
O	169	174	boost
O	175	181	versus
O	182	184	no
O	185	190	boost
O	190	191	"
O	192	197	trial
O	197	198	.

O	199	201	To
O	202	213	investigate
O	214	217	the
O	218	224	impact
O	225	227	of
O	228	231	the
O	232	237	boost
O	238	242	dose
O	243	245	to
O	246	249	the
O	250	257	primary
O	258	264	tumour
O	265	268	bed
O	269	271	in
O	272	275	the
O	276	285	framework
O	286	288	of
O	289	295	breast
O	296	306	conserving
O	307	314	therapy
O	315	317	on
O	318	323	local
O	324	331	control
O	331	332	,
O	333	341	cosmetic
O	342	349	results
O	349	350	,
O	351	359	fibrosis
O	360	363	and
O	364	371	overall
O	372	380	survival
O	381	384	for
B-eligibility	385	393	patients
I-eligibility	394	398	with
I-eligibility	399	404	early
I-eligibility	405	410	stage
I-eligibility	411	417	breast
I-eligibility	418	424	cancer
O	424	425	.

B-control-participants	426	430	Five
I-control-participants	431	439	thousand
I-control-participants	440	444	five
I-control-participants	445	452	hundred
I-control-participants	453	456	and
I-control-participants	457	462	sixty
I-control-participants	462	463	-
I-control-participants	463	467	nine
O	468	476	patients
O	477	482	after
O	483	493	lumpectomy
O	494	502	followed
O	503	505	by
O	506	511	whole
O	512	518	breast
O	519	530	irradiation
O	531	533	of
O	534	536	50
O	537	539	Gy
O	540	544	were
O	545	555	randomised
O	555	556	.

O	557	562	After
O	563	564	a
O	565	580	microscopically
O	581	589	complete
O	590	600	lumpectomy
O	601	602	(
B-intervention-participants	602	606	5318
O	607	615	patients
O	615	616	)
O	616	617	,
O	618	621	the
O	622	627	boost
O	628	633	doses
O	634	638	were
O	639	645	either
O	646	647	0
O	648	650	or
O	651	653	16
O	654	656	Gy
O	656	657	,
O	658	663	while
O	664	669	after
O	670	671	a
O	672	687	microscopically
O	688	698	incomplete
O	699	700	(
O	700	703	251
O	704	712	patients
O	712	713	)
O	714	724	lumpectomy
O	725	738	randomisation
O	739	742	was
O	743	750	between
O	751	753	10
O	754	757	and
O	758	760	26
O	761	763	Gy
O	763	764	.

O	765	768	The
O	769	776	results
O	777	779	at
O	780	781	a
O	782	788	median
O	789	795	follow
O	795	796	-
O	796	798	up
O	799	801	of
O	802	804	10
O	805	810	years
O	811	814	are
O	815	824	presented
O	824	825	.

O	826	828	At
O	829	831	10
O	832	837	years
O	837	838	,
O	839	842	the
B-outcome	843	853	cumulative
I-outcome	854	863	incidence
I-outcome	864	866	of
I-outcome	867	872	local
I-outcome	873	883	recurrence
O	884	887	was
B-cv-bin-percent	888	890	10
I-cv-bin-percent	890	891	.
I-cv-bin-percent	891	892	2
I-cv-bin-percent	892	893	%
O	894	900	versus
B-iv-bin-percent	901	902	6
I-iv-bin-percent	902	903	.
I-iv-bin-percent	903	904	2
I-iv-bin-percent	904	905	%
O	906	909	for
O	910	913	the
O	914	915	0
O	916	918	Gy
O	919	922	and
O	923	926	the
O	927	929	16
O	930	932	Gy
O	933	938	boost
O	939	945	groups
O	946	947	(
O	947	948	p
O	949	950	<
O	951	952	0
O	952	953	.
O	953	957	0001
O	957	958	)
O	959	962	and
B-iv-bin-percent	963	965	17
I-iv-bin-percent	965	966	.
I-iv-bin-percent	966	967	5
I-iv-bin-percent	967	968	%
O	969	975	versus
B-iv-bin-percent	976	978	10
I-iv-bin-percent	978	979	.
I-iv-bin-percent	979	980	8
I-iv-bin-percent	980	981	%
O	982	985	for
O	986	989	the
O	990	992	10
O	993	996	and
O	997	999	26
O	1000	1002	Gy
O	1003	1008	boost
O	1009	1015	groups
O	1015	1016	,
O	1017	1029	respectively
O	1030	1031	(
O	1031	1032	p
O	1033	1034	>
O	1035	1036	0
O	1036	1037	.
O	1037	1038	1
O	1038	1039	)
O	1039	1040	.

O	1041	1046	There
O	1047	1050	was
O	1051	1053	no
O	1054	1067	statistically
O	1068	1079	significant
O	1080	1091	interaction
O	1092	1095	per
O	1096	1099	age
O	1100	1105	group
O	1106	1109	but
B-outcome	1110	1121	recurrences
O	1122	1128	tended
O	1129	1131	to
O	1132	1137	occur
O	1138	1145	earlier
O	1146	1148	in
O	1149	1156	younger
O	1157	1165	patients
O	1165	1166	.

O	1167	1169	As
O	1170	1177	younger
O	1178	1186	patients
O	1187	1190	had
O	1191	1192	a
O	1193	1199	higher
B-outcome	1200	1210	cumulative
I-outcome	1211	1215	risk
I-outcome	1216	1218	of
I-outcome	1219	1224	local
I-outcome	1225	1232	relapse
O	1233	1235	by
O	1236	1240	year
O	1241	1243	10
O	1243	1244	,
O	1245	1248	the
O	1249	1258	magnitude
O	1259	1261	of
O	1262	1265	the
O	1266	1274	absolute
O	1275	1277	10
O	1277	1278	-
O	1278	1282	year
O	1283	1287	risk
O	1288	1297	reduction
O	1298	1306	achieved
O	1307	1311	with
O	1312	1315	the
O	1316	1321	boost
O	1322	1331	decreased
O	1332	1336	with
O	1337	1347	increasing
O	1348	1351	age
O	1351	1352	.

O	1353	1364	Development
O	1365	1367	of
O	1368	1376	fibrosis
O	1377	1380	was
O	1381	1394	significantly
O	1395	1404	dependent
O	1405	1407	on
O	1408	1411	the
O	1412	1417	boost
O	1418	1422	dose
O	1423	1427	with
O	1428	1429	a
B-outcome	1430	1432	10
I-outcome	1432	1433	-
I-outcome	1433	1437	year
I-outcome	1438	1442	rate
I-outcome	1443	1446	for
I-outcome	1447	1453	severe
I-outcome	1454	1462	fibrosis
O	1463	1465	of
B-cv-bin-percent	1466	1467	1
I-cv-bin-percent	1467	1468	.
I-cv-bin-percent	1468	1469	6
I-cv-bin-percent	1469	1470	%
O	1471	1476	after
O	1477	1478	0
O	1479	1481	Gy
O	1481	1482	,
B-iv-bin-percent	1483	1484	3
I-iv-bin-percent	1484	1485	.
I-iv-bin-percent	1485	1486	3
I-iv-bin-percent	1486	1487	%
O	1488	1493	after
O	1494	1496	10
O	1497	1499	Gy
O	1499	1500	,
B-iv-bin-percent	1501	1502	4
I-iv-bin-percent	1502	1503	.
I-iv-bin-percent	1503	1504	4
I-iv-bin-percent	1504	1505	%
O	1506	1511	after
O	1512	1514	16
O	1515	1517	Gy
O	1518	1521	and
B-iv-bin-percent	1522	1524	14
I-iv-bin-percent	1524	1525	.
I-iv-bin-percent	1525	1526	4
I-iv-bin-percent	1526	1527	%
O	1528	1533	after
O	1534	1536	26
O	1537	1539	Gy
O	1539	1540	,
O	1541	1553	respectively
O	1553	1554	.

O	1555	1557	An
O	1558	1566	increase
O	1567	1569	of
O	1570	1573	the
O	1574	1578	dose
O	1579	1583	with
O	1584	1586	16
O	1587	1589	Gy
O	1590	1598	improved
O	1599	1604	local
O	1605	1612	control
O	1613	1616	for
O	1617	1625	patients
O	1626	1631	after
O	1632	1633	a
O	1634	1642	complete
O	1643	1653	lumpectomy
O	1654	1658	only
O	1658	1659	.

O	1660	1663	The
O	1664	1675	development
O	1676	1678	of
O	1679	1687	fibrosis
O	1688	1691	was
O	1692	1699	clearly
O	1700	1704	dose
O	1705	1714	dependent
O	1714	1715	.

O	1716	1720	With
O	1721	1723	10
O	1724	1729	years
O	1730	1736	median
O	1737	1743	follow
O	1743	1744	-
O	1744	1746	up
O	1746	1747	,
O	1748	1750	no
O	1751	1757	impact
O	1758	1760	of
O	1761	1769	survival
O	1770	1773	was
O	1774	1782	observed
O	1782	1783	.
